Virtual Library
Start Your Search
H. Long
Author of
-
+
P2.05 - Early Stage NSCLC (ID 706)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Early Stage NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.05-018 - Video-Assisted Thoracoscopic Surgery vs Thoracotomy for Early-Stage Non-Small Cell Lung Cancer: Short-Term Outcomes of a Randomized Trial (ID 9974)
09:30 - 09:30 | Author(s): H. Long
- Abstract
Background:
Video-assisted thoracoscopic surgery (VATS) has been rapidly gaining popularity worldwide in the treatment of early stage non–small cell lung cancer (NSCLC) because it is potentially less invasive. However, there has not been a large randomized controlled trial (RCT) to prove its superiority over thoracotomy. Therefore, a large multicenter RCT in China was designed and initialed in order to verify the role of VATS.
Method:
A non-inferiority phase 3 randomized controlled trial was undertaken at five tertiary centers in China. Patients aged 18-75 years who were diagnosed of clinically early-stage NSCLCs were randomized in a 1:1 ratio into VATS and thoracotomy groups. Radical lobectomy plus mediastinal lymph node dissection was the standard surgery as per protocol. The short-term outcomes including acute phase inflammatory reaction, performance status, postoperative pain, respiratory function and quality of life would be analyzed and reported in this article. Patients continue to be followed up for the primary endpoints (5-year overall and disease-free survival). This study is registered with the ClinicalTrials.gov, number NCT01102517.
Result:
Between January 2008 and March 2014, 508 patients were recruited and 481 were eligible for randomization. 236 patients were randomly assigned to the VATS group, while 245 to the thoracotomy group. Finally, 425 were eligible for analyses (215 and 210, respectively). For acute phase inflammatory reaction assessment, cytokines including IL-2、IL-4、IL-6、IL-10、TNF-α and IFN-γ were tested in different time points within 48 hours postoperatively. No significant difference was found between the 2 groups except IL-6 (P=0.0411). Patients who received VATS procedures had better daily Karnofsky performance status in the first week (P=0.0029). Visual analogue scale (VAS) was applied for pain assessment at the time points of postoperative day 1 to 7 and every 3 months within the first year. Our study showed VATS was superior to open procedures in pain control within the first week after surgery (P=0.0274). However, this benefit diminished within the year. Spirometry was tested at the time points of day 7, 1 and 3 months postoperatively. Both FEV1 and FVC were better preserved in VATS group throughout the time (P=0.0005). Finally, lung cancer symptom scale (LCSS) was used to evaluate the quality of life, and there was no significant difference demonstrated between the 2 groups within the first year after surgery.
Conclusion:
The short-term outcome of our trial has demonstrated that VATS may be superior to thoracotomy in the surgical treatment for NSCLC in terms of short-term performance status, pain control and respiratory function preservation.
-
+
P2.14 - Radiotherapy (ID 715)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Radiotherapy
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.14-004 - Comparable Local Controls after Twice-Daily and Once-Daily Chest Radiotherapy in Extensive Stage Small Cell Lung Cancer (ID 8788)
09:30 - 09:30 | Author(s): H. Long
- Abstract
Background:
The optimal radiation schedule for small cell lung cancer (SCLC) has not yet fully established. This study was designed to compare the clinical outcomes between twice- and once-daily radiotherapy in the treatment of SCLC.
Method:
One hundred and twenty-four consecutive patients diagnosed with extensive stage SCLC and treated with chemoradiotherapy were retrospectively reviewed. Either twice-daily hyper-fractionated irradiation (45 Gy/30 fractions/BID), or alternative schedules, including hypo-fractionated (45 Gy/15 fractions/QD) or conventionally fractionated (50 Gy/25 fractions/QD or 60 Gy/30 fractions/QD) radiation was delivered, with etoposide and platinum prescribed concurrently or sequentially. Local controls and overall survivals were calculated and compared between twice- and once-daily schedules based on Kaplan-Meier method. Toxicities were record according to Common Terminology Criteria Adverse Events.
Result:
There were 67 and 57 patients received twice- and once-daily chest radiotherapy, respectively. With a median follow-up of 27 and 24 months, the local control rates were reported 64.2% and 63.2%. The 2-year estimated local progression-free survival rates were similar (61.6% vs 61.0%, p=0.90). Progressive disease identified three months after radiotherapy was correlated to increased local failure (p=0.026). There was no difference between the incidences of grade 3-4 toxicities between twice- and once-daily schedules (23.9% vs 12.3%, p=0.16).
Conclusion:
Either twice- (45 Gy/30 fractions/BID) or once-daily (45 Gy/15 fractions/QD, 50 Gy/25 fractions/QD, 60 Gy/30 fractions/QD) radiation schedule could be considered in the treatment of SCLC, resulting in comparable local control and toxicities.
